A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular Hemodialysis

Pfizer

Status and phase: Completed; Phase 1

Conditions: Renal Dialysis; Pharmacokinetics

Treatments: Drug: PD-0332334

Study type: Interventional

Funder types: Industry

Identifiers

NCT00730145

A5361032

Details and patient eligibility

About

1. Quantify how much PD-0332334 is removed from the blood with hemodialysis
2. Investigate the pharmacokinetics of a single dose of PD-0332334 in subjects receiving regular hemodialysis treatments.
3. Investigate the safety and tolerability of a single dose of PD-0332334 in subjects receiving hemodialysis.

Full description

Assess the elimination of PD-0332334 from the blood with hemodialysis

Enrollment: 8 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients receiving regular hemodialysis
• Male or female patients 18 to 65 years

Exclusion criteria

• Severe heart failure
• Renal transplant or renal allograft
• Illicit drug use (with the exception of prescribed sedatives)

Trial design

8 participants in 1 patient group

PD-0332334

Experimental group

Treatment:

Drug: PD-0332334